Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.

Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R, Akehurst R, Snowden J.

Bone Marrow Transplant. 2010 Jun;45(6):1014-21. doi: 10.1038/bmt.2009.305. Epub 2009 Oct 26.

PMID:
19855441
2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
3.

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.

Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2006 Dec;10(49):iii-iv, ix-xi, 1-157. Review.

4.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

5.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

6.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
7.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

8.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

9.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

10.

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J.

Health Technol Assess. 2006 Mar;10(7):iii, ix-118. Review.

11.

Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling.

Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F.

Health Technol Assess. 2007 Oct;11(38):iii-iv, ix-66. Review.

12.

Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation.

Clar C, Cummins E, McIntyre L, Thomas S, Lamb J, Bain L, Jobanputra P, Waugh N.

Health Technol Assess. 2005 Dec;9(47):iii-iv, ix-x, 1-82. Review.

13.
14.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

15.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

17.

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.

Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.

Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. Review.

18.

Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial).

Michaels JA, Campbell WB, Brazier JE, Macintyre JB, Palfreyman SJ, Ratcliffe J, Rigby K.

Health Technol Assess. 2006 Apr;10(13):1-196, iii-iv. Review.

19.

Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model.

Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C.

Health Technol Assess. 2006 Nov;10(44):iii-iv, ix-x, 1-210. Review.

20.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk